Good morning All,
So not long now for an update on Janssen collaboration. It does seem like forever, but CREDENCE was a very large study, 4000 plus cohort. Within the next 2 months as @katy & others have pointed out.
Some news on Invokana FYI, extra indications for kidney disease & cardiovascular disease granted in Canada. EU EMA decision is due anytime now (Fast track application accepted in August 2019 by EMA ~150 days timeframe) and important as we already have CE Mark for PromarkerD in EU.
https://www.google.com.au/amp/s/finance.yahoo.com/amphtml/news/health-canada-approves-indication-invokana-123100771.html
Had a quick read through the quarterly, the below I think is a very important addition for PIQ in analytics. We are already engaged in clinical trial analysis for a bio similar for Xolair (Omalizumab). This space is HUGE & I think a very forward thinking addition to PIQ’s services:
”Proteomics International also took advantage of the downtime associated with its equipment upgrade to develop and launch a new specialist service for glycan analysis of biosimilars. This is an important addition to the Company's portfolio of services that are used to assess the quality of a biosimilar product, with the use of biosimilar drugs in the treatment of cancers continuing to expand.”
Also good to see PIQ are now continuing on with Endometriosis & Giardia tests in their pipeline. Maybe in earlier stages of development, but valuable all the same.
SP remains on a bit of a roller coaster ride, I’m not sure if that also may have something to do with concerns about what will happen in markets with the Corona virus affect & China? & not just our Quarterly.
Investment in analytics & equipment is vital to PIQ to continue their good work, & that doesn’t come cheap. If you want to tie in the whole Global Warming debate here too, I guess you could, with agricultural & marine analysis & drought. The world still needs to be fed.
Just a couple of thoughts. Have a great weekend all.
- Forums
- ASX - By Stock
- PIQ
- Ann: Appendix 4C - December 2019 Quarterly Report
Ann: Appendix 4C - December 2019 Quarterly Report, page-9
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PIQ (ASX) to my watchlist
|
|||||
Last
85.0¢ |
Change
-0.005(0.58%) |
Mkt cap ! $111.3M |
Open | High | Low | Value | Volume |
86.0¢ | 86.5¢ | 83.5¢ | $147.2K | 173.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 18208 | 83.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
85.0¢ | 12633 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 6256 | 0.835 |
3 | 33860 | 0.830 |
1 | 1212 | 0.825 |
1 | 3646 | 0.820 |
1 | 7800 | 0.815 |
Price($) | Vol. | No. |
---|---|---|
0.850 | 12633 | 1 |
0.870 | 10000 | 1 |
0.875 | 13499 | 2 |
0.880 | 40101 | 3 |
0.890 | 13245 | 1 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
PIQ (ASX) Chart |